- Home
- RIGL vs EIC Comparison
RIGL vs EIC Comparison
Compare RIGL & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- EIC
- Stock Information
- Founded
- RIGL 1996
- EIC N/A
- Country
- RIGL United States
- EIC United States
- Employees
- RIGL N/A
- EIC N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- EIC Finance/Investors Services
- Sector
- RIGL Health Care
- EIC Finance
- Exchange
- RIGL Nasdaq
- EIC Nasdaq
- Market Cap
- RIGL 335.5M
- EIC 348.9M
- IPO Year
- RIGL 2000
- EIC 2019
- Fundamental
- Price
- RIGL $38.85
- EIC $13.86
- Analyst Decision
- RIGL Buy
- EIC Strong Buy
- Analyst Count
- RIGL 5
- EIC 1
- Target Price
- RIGL $38.20
- EIC $17.50
- AVG Volume (30 Days)
- RIGL 995.6K
- EIC 234.9K
- Earning Date
- RIGL 08-05-2025
- EIC 08-12-2025
- Dividend Yield
- RIGL N/A
- EIC 11.24%
- EPS Growth
- RIGL N/A
- EIC N/A
- EPS
- RIGL 5.43
- EIC 0.70
- Revenue
- RIGL $267,921,000.00
- EIC $55,581,156.00
- Revenue This Year
- RIGL $59.93
- EIC $37.84
- Revenue Next Year
- RIGL N/A
- EIC $23.33
- P/E Ratio
- RIGL $7.15
- EIC $19.94
- Revenue Growth
- RIGL 105.62
- EIC 56.39
- 52 Week Low
- RIGL $12.66
- EIC $12.10
- 52 Week High
- RIGL $43.72
- EIC $16.71
- Technical
- Relative Strength Index (RSI)
- RIGL 68.57
- EIC 70.39
- Support Level
- RIGL $39.00
- EIC $12.10
- Resistance Level
- RIGL $42.08
- EIC $13.15
- Average True Range (ATR)
- RIGL 2.32
- EIC 0.18
- MACD
- RIGL -0.37
- EIC 0.13
- Stochastic Oscillator
- RIGL 53.26
- EIC 97.37
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.